Low doses of psychostimulants produce beneficial behavioral effects in ADHD patients but the mechanisms underlying the response are not understood. Here we use the hyperactive mouse mutant coloboma to identify D2-like dopamine receptor subtypes that mediate the hyperactivity and response to amphetamine; we have previously demonstrated that D1-like dopamine receptors are not involved. Targeted deletion of the D2, but not the D3 or the D4, dopamine receptor in coloboma mice eliminated the hyperactivity; depleting D2 dopamine receptors also restored the excess dopamine overflow that may drive the hyperactivity to normal concentrations. Similar to its effects on ADHD patients, amphetamine reduced the hyperactivity of coloboma mice. The D2 dopamine receptor-selective antagonist L-741,626, but not D3 or D4 dopamine receptor-selective antagonists, blocked the amphetamine-induced reduction in locomotor activity. Thus, the D2 dopamine receptor subtype mediates both the hyperactivity and response to amphetamine, suggesting a specific target for novel therapeutics in ADHD.
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A familiar feature of attention deficit hyperactivity disorder (ADHD) is the response to psychostimulants such as methylphenidate and amphetamine. In ADHD patients, stimulants reduce excess motor activity and enhance concentration. The reduction in physical activity in ADHD patients after psychostimulant treatment is supported by studies using subjective rating scales and objective measures such as actometers, respiration calorimetry and microwave motor activity detectors (Arnold et al., 1972 (Arnold et al., , 1978 Butte et al., 1999; Elia et al., 1991; Evans et al., 1986; Rapoport et al., 1978) .
Because the primary treatment for ADHD is stimulant medication, research has focused on dopamine. Imaging experiments have identified dopamine transporters predominantly in the caudatoputamen as methylphenidate's site of action (Wang et al., 1995) . SPECT and PET studies in ADHD patients have also demonstrated decreased metabolic activity in the basal ganglia (Lou et al., 1989 (Lou et al., , 1990 , a region that contains high concentrations of dopamine and dopamine receptors. Assessments of catecholamine metabolites in cerebral spinal fluid of ADHD children support the imaging studies, demonstrating a positive correlation between the dopamine metabolite homovanillic acid and the degree of hyperactivity (Castellanos et al., 1994) .
Although dopamine is implicated in the pathophysiology and treatment of ADHD, there is little evidence implicating specific dopamine receptor subtypes. The lack of identified receptor targets is due primarily to the entirely non-selective action of psychostimulants, which increase the extracellular concentration of monoamines, resulting in the broad activation of many receptor subtypes. In the absence of an unambiguous therapeutic mechanism of action, specific treatment strategies are not forthcoming. Although determining the receptors mediating the positive behavioral effects of psychostimulants in humans would require years of correlative experiments, animal models of ADHD provide an opportunity to explore directly both pathogenic and therapeutic mechanisms.
It is not feasible to reproduce the entire spectrum of a neuropsychiatric disorder in an animal because of the complexity of the behavioral pathology and because some phenotypes are not credibly mimicked in animals. Therefore, animal models of psychiatric disorders, including ADHD, focus on specific quantifiable behavioral features. The pathophysiological insight gained through the analysis of discrete quantifiable behaviors then provides a foundation for understanding more complex features of the disorder. For ADHD, hyperactivity and the response to psychostimulants are features of the disorder convincingly modeled in rodents. All models of ADHD exhibit hyperactivity, including coloboma mice. These mice exhibit inattention, impulsivity and hyperactivity attributable to a hemizygous Neurobiology of Disease 37 (2010) 228-236 
